Rapid bioanalytical data to meet your program's milestones
Delivering rapid bioanalytical data is critical to meeting milestones faster in drug development.
Highly sensitive bioanalytical techniques enable the identification and quantification of analytes, such as small molecules, peptides, proteins, nucleic acids, and metabolites, all from very small volumes of biological samples.
Quotient Sciences are experts in the development, validation, and application of bioanalytical assays. We can help you learn more about your molecule and accelerate your drug program.

GLP & GCP accredited laboratories
Our accredited facilities provide comprehensive bioanalytical support to studies at all stages of development.
Short lead times & rapid turnaround for data
We deliver rapid bioanalytical data in the discovery, preclinical, and clinical stages with advanced equipment and systems, including: LC-MS/MS, LC-HR-MS, ICP-MS, ICP-MS/MS, GC-MS, and GC-MS/MS.
Over 40 years of scientific expertise in bioanalytical assays
We are experts in the development, validation, and application of bioanalytical assays with over 40 years of scientific expertise.
Over 400 bioanalytical assays developed, validated, and applied.
We have developed more than 400 methods (LC-MS, GC-MS, ICP-MS) for our customers, with expertise in areas such as insulin analogues & polypeptide drugs, elemental analysis, volatile drugs, and biomarkers.
Integrated toxicokinetics & pharmacokinetics (TK & PK)
We offer expert toxicokinetics (TK) and pharmacokinetics (PK) data analysis and reporting to support pre-clinical and clinical studies. Working together with our expert PK team, we can reduce the risk of downstream delays in later phases of your drug development.
At every stage, we can help you better understand your drug's fate in the human body.
Combining our development and validation experience of over 400 bioanalytical assays, along with our integrated service lines, we can ensure that critical decision-making data are rapidly processed, robust, and reliable.
Using advanced mass spectrometry equipment, we can identify and quantify analytes to determine if, and how, a drug is metabolized in the body. In conjunction with the range of extraction technologies available, we can support you in the development of highly selective and sensitive assays.
Bioanalytical services for small molecule drug development
Our experts can quickly develop, validate, and implement bioanalytical LC-MS, GC-MS, and ICP-MS assays for small- and large-molecule drugs, biomarkers, and elements in compliance with regulatory standards.
Broad range of platforms
- Liquid chromatography with mass spectrometry (LC-MS)
- Inductively coupled plasma mass spectrometry (ICP-MS)
- Gas chromatography with mass spectrometry (GC-MS)
High-resolution mass spectrometry
- Liquid chromatography with ion-trap mass spectrometry (LC-TRAP-MS)
- Liquid chromatography with time-of-flight mass spectrometry (LC-TOF-MS)
Global compliance and regulatory
- Good Laboratory Practice (GLP)- and Good Clinical Practice (GCP)-accredited laboratories
- US Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- UK Medicines and Healthcare products Regulatory Agency (MHRA)
Specialist areas of expertise
- Insulin analogues and polypeptide drugs
- Elemental analysis
- Volatile drugs and biomarkers
Comprehensive bioanalytical support at every stage of your drug program
Our dedicated bioanalytical chemists are globally recognized and have decades of experience supporting all stages of drug development. Contact us today discuss your next program.
Preclinical
- Drug metabolism and pharmacokinetics (DMPK)
- Pre-clinical pharmacology
- TK, including GLP toxicology studies
- Dose escalation and selection
Phase I
- First-in-human (FIH) single ascending dose (SAD) and multiple ascending dose (MAD) studies
- Relative bioavailability and PK studies
- Clinical pharmacology programs
- Drug-drug interaction (DDI) studies
- Bioequivalence studies
- 14C absorption distribution, metabolism, and excretion (ADME) and mass balance studies
- Pharmacodynamic (PD), metabolite and biomarker analysis
Phase II and III
- Global, multi-center trials
- Relative bioavailability and PK
- PD, metabolite, and biomarker analysis
A closer look at our equipment and applications
Instrumentation | Applications |
---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expert insight in bioanalysis:
More BlogsSee how we can help you with your next drug program.